https://www.pharmaceutical-technology.com/data-insights/revumenib-citrate-syndax-pharmaceuticals-refractory-acute-myeloid-leukemia-likelihood-of-approval/
Revumenib citrate by Syndax Pharmaceuticals for Refractory Acute Myeloid Leukemia: Likelihood of...
Jan 20, 2025 - Revumenib citrate is under clinical development by Syndax Pharmaceuticals and currently in Phase II for Refractory Acute Myeloid Leukemia.
acute myeloid leukemiarevumenibcitratepharmaceuticalsrefractory
https://healthtree.org/video/YMt1KVzJ5lHK38rPdcs3
New Therapies in AML - Menin Inhibitor Revumenib (SNDX-5613) | Eytan M. Stein, MD | ASH 2022
Eytan M. Stein presents New Therapies in AML at ASH 2022.
newtherapiesamlmenininhibitor